CD8A and neoplasm: This finding suggests that increased Ki67+ populations in circulating PD-1+CD8+ T cells after PD-1 therapy could predict the responsiveness of PD-1 therapy in various tumor types (Kamphorst et al., 2017a; Kim K. H. et al., 2019).